Drug Pricing
Expert articles and analysis related to drug pricing.
AI Summary — Last 24 Hours
President Trump said all 50 states, Washington, DC, and Puerto Rico will participate in the Medicaid “GENEROUS” most-favored-nation drug pricing model, under which manufacturers would provide supplemental rebates to align Medicaid net prices with lower international benchmarks—potentially reshaping state Medicaid pharmacy budgets, rebate flows, and formulary leverage for managed care plans and safety-net providers. Key operational details remain unclear, including covered drugs, rebate mechanics, CMS/state implementation timelines, and interaction with existing Medicaid best-price rules and 340B, creating near-term uncertainty for VBC contracts that rely on predictable drug-cost benchmarks and total-cost-of-care targets. Meanwhile, AHIP is escalating the payer case that brand-drug price hikes are driving premiums, reinforcing the policy tension between manufacturer pricing, PBM/rebate transparency, and affordability goals in Medicaid and Medicare risk arrangements (Endpoints News; STAT).
Related Articles
All 50 states sign up for most favored nation prices under Medicaid, Trump says
President Donald Trump on Friday announced that all 50 states, Washington, DC, and Puerto Rico will participate in a new drug pricing model under which pharma companies will provide supplemental rebat...
White House Extends MFN Pricing to Every State Medicaid Program
Fact-Check: Brand Drugmakers’ Relentless Price Hikes Cause Higher Premiums
Fact-Check: Brand Drugmakers’ Relentless Price Hikes Cause Higher Premiums  AHIP
STAT+: Trump touts pharma deals to offer cheaper drugs to state Medicaid programs
Every state will participate in the GENEROUS program, but many of the details are unknown.
Generic Drug Costs Burdening Patients as Much as Brand Name Options
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
How Rebate Timing Distorts a Pharmacy's 340B Books
See It Coming: A Predictive Approach To Drug Shortage Management
See It Coming: A Predictive Approach To Drug Shortage Management  Becker's Payer Issues